ライフサイエンスコーパス: vitamin D3

1 nd thus must rely on cutaneous production of vitamin D3.

2 potentially toxic microbiome metabolite; and vitamin D3.

3 in D pathway genes on response to adjunctive vitamin D3.

4 se effects were increased by the presence of vitamin D3.

5 other gastroprotective agents combined with vitamin D3.

6 venous calcium gluconate, magnesium and oral vitamin D3.

7 variability: -0.37 mm Hg) compared to 800 IU vitamin D3 (0.11 mm Hg; difference: -0.48 mm Hg; 95% CI:

8 o simvastatin 20 mg tablets twice-daily plus vitamin D3 1,000 international units capsules twice-dail

9 ut to define the role of 1alpha,25-dihydroxy vitamin D3 (1,25D) in regulating functional responses of

10 in 1 of the following 8 groups: 2000 IU/d of vitamin D3, 1 g/d of omega-3s, and a strength-training e

11 ,25-dihydroxycholecalciferol (1,25-dihydroxy-vitamin D3; 1,25-VitD3) in the cardiovascular system is

12 Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks

13 obese children, whether supplementation with vitamin D3 1000 or 2000 IU/d is more effective than 600

14 Daily oral supplementation with vitamin D3 (1000 IU) or calcium carbonate (1200 mg eleme

15 Daily supplementation with vitamin D3 (1000 IU), calcium (1200 mg), or both after r

16 assigned 2259 participants to receive daily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), bo

17 group who received one dosage of daily oral vitamin D3 (1000 IU), or a group who received 2 dosages

18 ts were randomly assigned to receive 2000 IU vitamin D3, 1000 mg fish oil, or placebo daily for 6 mo.

19 d were randomly allocated to 1 of 3 doses of vitamin D3 [12,000 international units (IU), 24,000 IU,

20 ed that 1,25-vitamin D3-deficient 25-hydroxy-vitamin-D3-1alpha-hydroxylase knockout mice and 1,25-vit

21 for 7 days, and vitamin K2 (30 mg/kg) and/or vitamin D3 (2 mug/kg) were administered for 10 days in t

22 69 were randomly assigned as follows: 27 to vitamin D3; 20 to fish oil; and 22 to placebo.

23 ompared with placebo, participants receiving vitamin D3 (200,000 international units) demonstrated re

24 a group who received 2 dosages of daily oral vitamin D3 (2000 IU).

25 ed assignment in a 2 x 2 factorial design to vitamin D3 (2000 IU/d of cholecalciferol) and fish oil o

26 Participants were randomized to receive vitamin D3 (2000 IU/d) and omega-3 fatty acids (eicosape

27 Vitamin D3 (2400 IU/d; n = 315) or matching placebo tabl

28 DA measurement [concentration of vitamin D2, vitamin D3, 25(OH)D2, and 25(OH)D3] at 2 wk and 2 mo pos

29 metabolites lacking a 1alpha-hydroxyl group (vitamin D3, 25-hydroxyvitamin D3, and 24R,25-dihydroxyvi

30 e also analyzed along with plasma 25-hydroxy vitamin D3 (25D) detection.

31 l, we investigated the effect of long-acting vitamin D3 (400,000 IU) on sputum neutrophils and eosino

32 Participants were randomized to vitamin D3, 4000 IU/d (n = 96), or placebo (n = 96) for

33 healthy; 2) periodontitis; 3) SRP; 4) SRP + vitamin D3; 5) SRP + vitamin K2; and 6) SRP + vitamins K

34 igned to receive monthly treatment with oral vitamin D3 (50,000 IU; n = 209) or an identical placebo

35 jects were randomly assigned to receive oral vitamin D3 [50,000 IUs (1.25 mg) thrice weekly for 8 wk

36 Adjunctive vitamin D3 accelerated sputum culture conversion in pati

37 ctivation, and clearance was associated with vitamin D3 administration.

38 n = 265); vitamin D3 and exercise (n = 275); vitamin D3 alone (n = 272); omega-3s and exercise (n = 2

39 synthesis of anti- and syn-1,3 amino alcohol vitamin D3 analogue intermediates in half the steps and

40 ffect of 1,25-vitamin D3 deficiency and 1,25-vitamin D3 and 1,25-vitamin D2 repletion on proteinuria

41 in D3 + calcium group) received 2000 IU/d of vitamin D3 and 1500 mg/d of calcium; the placebo group r

42 We investigated the retention of vitamin D3 and 25-hydroxyvitamin D3 in eggs, vitamin D3

43 et and purchase date on the concentration of vitamin D3 and 25-hydroxyvitamin D3.

44 R- and 20S-isomers of 25-hydroxy-2-methylene-vitamin D3 and 3-desoxy-1alpha,25-dihydroxy-2-methylene-

45 fish oil or placebo; 9181 were randomized to vitamin D3 and 9172 were randomized to matching placebo.

46 D status and dose-response, we performed two vitamin D3 and calcium clinical supplementation trials i

47 D level of 32.8 ng/mL, supplementation with vitamin D3 and calcium compared with placebo did not res

48 To determine if dietary supplementation with vitamin D3 and calcium reduces the risk of cancer among

49 r with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secr

50 n = 264); vitamin D3 and omega-3s (n = 265); vitamin D3 and exercise (n = 275); vitamin D3 alone (n =

51 zation enhanced the ionisation efficiency of vitamin D3 and its isomers in UHPLC-MS/MS and improved t

52 Within the limitations of this study, vitamin D3 and K2 alone or in combination did not affect

53 rred among 58 participants (n = 32 receiving vitamin D3 and n = 26 receiving placebo) and gastrointes

54 trength-training exercise program (n = 264); vitamin D3 and omega-3s (n = 265); vitamin D3 and exerci

55 and docosahexaenoic acid; 1 g/d) (n = 370), vitamin D3 and placebo (n = 333), placebo and omega-3 fa

56 Baseline serum 25(OH)D concentrations in the vitamin D3 and placebo group were 30.7 and 30.0 nmol/L,

57 ilar median culture-conversion times between vitamin D3 and placebo groups [29 and 27 d, respectively

58 There were no differences between the vitamin D3 and placebo groups in time to next pulmonary

59 rates were also similar (84.0% and 82.1% for vitamin D3 and placebo, respectively; P = 0.99).

60 and pre-vitamin D3 takes place to form trans-vitamin D3 and tachysterol, respectively.

61 LDL-cholesterol concentrations between oral vitamin D3 and UVB groups (difference in median of oral

62 min D3 in eggs, vitamin D3 in margarine, and vitamin D3 and vitamin D2 in bread.

63 The two major forms of vitamin D, vitamin D3 and vitamin D2, are metabolized in the liver

64 The synergistic effects of vitamin D3 and vitamin K2 on bone loss prevention have b

65 This study evaluates the effects of vitamin D3 and vitamin K2 supplementation in conjunction

66 etry (LC-MS/MS) method for quantification of vitamins D3 and D2 in serum and to explore the potential

67 high-throughput LC-MS/MS method to quantify vitamins D3 and D2 in serum.

68 Fibroblast growth factor-23, 1,25-(OH)2-vitamin D3, and insulin concentrations did not respond,

69 issected the basis for the resistance to the vitamin D3 antitumor properties and specifically examine

70 the literature as to whether vitamin D2 and vitamin D3 are equally effective in increasing and maint

71 While the antiinflammatory effects of vitamin D3 are well described, we found that, conversely

72 All women received 400 IU/d of vitamin D3 as part of usual pregnancy care.

73 Vitamin D3 at 3750 IU/d did not improve HOMA-IR compared

74 -activity relationship study for a series of vitamin D3-based (VD3) analogues that incorporate aromat

75 on in the 2 ethnic groups combined, both the vitamin D3 biscuit and the vitamin D3 juice groups showe

76 in plasma campesterol concentrations in the vitamin D3 but not placebo group (P-interaction = 0.011)

77 lation of immune pathway signaling with oral vitamin D3 but significant downregulation with UVB.Corre

78 rs was 0.042 (95% CI, 0.032 to 0.056) in the vitamin D3 + calcium group and 0.060 (95% CI, 0.048 to 0

79 cluded renal calculi (16 participants in the vitamin D3 + calcium group and 10 in the placebo group),

80 and elevated serum calcium levels (6 in the vitamin D3 + calcium group and 2 in the placebo group).

81 droxyvitamin D levels were 43.9 ng/mL in the vitamin D3 + calcium group and 31.6 ng/mL in the placebo

82 irmed in 109 participants, 45 (3.89%) in the vitamin D3 + calcium group and 64 (5.58%) in the placebo

83 The treatment group (vitamin D3 + calcium group) received 2000 IU/d of vitami

84 to receive either placebo or a high dose of vitamin D3 (cholecalciferol) one hour after experimental

85 ish safety and efficacy of high-dose 25 (OH) vitamin D3 (cholecalciferol) supplementation in patients

86 maximum dose of 20kJ/m(2) produced 3.5-4mug vitamin D3/cm(2) pig skin.

87 We therefore investigated whether vitamin D3 (colecalciferol) supplementation would reduce

88 Vitamin D3 compared with placebo did not affect time to

89 ressive symptoms at baseline, treatment with vitamin D3 compared with placebo did not result in a sta

90 Results demonstrated a higher vitamin D3 concentration in free range (57.2+/-3.1mug/kg

91 Serum and SUBQ adipose tissue vitamin D3 concentrations increased proportionally to do

92 endent associations between myopia and serum vitamin D3 concentrations nor variants in genes associat

93 Serum and adipose tissue vitamin D3 concentrations were correlated, and the dose-

94 in vitamin D metabolic pathway genes, serum vitamin D3 concentrations, and years of education.

95 Odds ratios (ORs) of UVB, serum vitamin D3 concentrations, vitamin D single-nucleotide p

96 articipants were randomly assigned to 800 IU vitamin D3/d (intervention) or placebo.

97 tested whether 2000 IU is superior to 800 IU vitamin D3/d for cognitive performance among relatively

98 ts received 1000 mg elemental Ca with 400 IU vitamin D3/d or placebo (median follow-up: 6.5 y).

99 were assigned to 0 (placebo), 10, or 20 mug vitamin D3/d supplementation for 20 wk.

100 nmol/L in the groups receiving 10 and 20 mug vitamin D3/d, respectively, and decreased by 24.1 +/- 1.

101 L after 4 mo were given an additional 800 IU vitamin D3/d, whereas all other participants received pl

102 e randomly assigned to either 2000 or 800 IU vitamin D3/d.

103 To investigate whether novel pathways of vitamin D3 (D3) and 7-dehydrocholesterol (7DHC) metaboli

104 Vitamin D3 (D3) was encapsulated within a water-soluble

105 bitory via production of hedgehog-inhibiting vitamin D3 (D3).

106 total of 204 T2DM subjects received 2000 IU vitamin D3 daily for 12 months.

107 amin D3, or biscuit supplemented with 15 mug vitamin D3 daily for 12 wk.

108 Conversely, the measured bioaccessibility of vitamin D3 decreased in the following order: corn oil ap

109 The effect of 1,25-vitamin D3 deficiency and 1,25-vitamin D3 and 1,25-vitam

110 n impaired renal function also leads to 1,25-vitamin D3 deficiency as a result of reduced renal 1alph

111 This study demonstrates that 1,25-vitamin D3 deficiency directly leads to renal injury in

112 Herein, we showed that 1,25-vitamin D3-deficient 25-hydroxy-vitamin-D3-1alpha-hydrox

113 erular and tubulointerstitial damage in 1,25-vitamin D3-deficient animals, thereby preserving and res

114 e podocyte was significantly altered in 1,25-vitamin D3-deficient animals.

115 D3-1alpha-hydroxylase knockout mice and 1,25-vitamin D3-deficient rats develop podocyte injury and re

116 placebo, participants using simvastatin plus vitamin D3 demonstrated a greater decrease in number of

117 3 y, monthly supplementation with 100,000 IU vitamin D3 did not affect the incidence rate of kidney s

118 Vitamin D3 did not influence time to sputum culture conv

119 Vitamin D3 did not reduce the rate of first treatment fa

120 s 16.1 ng/mL vs 18.7 ng/mL for standard-dose vitamin D3 (difference, -2.6 ng/mL [95% CI, -6.6 to 1.4]

121 hibiting Hedgehog signaling, whereas dietary vitamin D3 does not.

122 beneficial effects were negated with higher vitamin D3 doses.

123 To protect vitamin D3 during cold storage and exposure to UV-light,

124 cts of Grisu(R) alone or in combination with vitamin D3 during oxidative stress or high acid expositi

125 y of maternal supplementation with 4400 IU/d vitamin D3 during the second and third trimesters of pre

126 The use of 2800 IU/d of vitamin D3 during the third trimester of pregnancy compa

127 that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevent

128 in which baseline 25(OH)D was accounted for, vitamin D3-egg and 25(OH)D3-egg groups were shown to hav

129 carrier oil type on the bioaccessibility of vitamin D3 encapsulated within oil-in-water nanoemulsion

130 in which status was expected to decline), 7 vitamin D3-enhanced eggs/wk, or seven 25(OH)D3-enhanced

131 omized to an initial oral dose of 200 000 IU vitamin D3 followed by 100 000 IU monthly (n = 2558) or

132 omized to an initial oral dose of 200,000 IU vitamin D3 followed by 100,000 IU monthly (n=2,558) or p

133 ne the impact of a single high-dose bolus of vitamin D3 followed by maintenance treatment given to ad

134 dose of 200 000 IU (5.0 mg) colecalciferol (vitamin D3) followed by monthly 100 000 IU (2.5 mg) cole

135 se (2000 IU) or standard dose (800 IU) daily vitamin D3 for 24 mo.

136 Daily doses of vitamin D3 for 3 years at 400 IU (n = 109), 4000 IU (n =

137 (4000 IU/d) versus low-dose (400 IU/d) oral vitamin D3 for 6 months.

138 ferences between high-dose and standard-dose vitamin D3 for tumor ORR (58% vs 63%, respectively; diff

139 e aimed to investigate whether vitamin D2 or vitamin D3 fortified in juice or food, at a relatively l

140 jects with CF were randomly assigned to oral vitamin D3 given as a single dose of 250,000 Internation

141 was not significantly different between the vitamin D3 group (609 depression or clinically relevant

142 240 patients were randomly allocated to the vitamin D3 group (n=122) and placebo group (n=118).

143 e included in the final analysis (237 in the vitamin D3 group and 238 in the placebo group).

144 A total of 36 participants (37.5%) in the vitamin D3 group and 33 (34.4%) in the placebo group had

145 3 years of life in 47 children (16%) in the vitamin D3 group and 57 children (20%) in the control gr

146 tal malformations in 17 neonates (5%) in the vitamin D3 group vs 23 neonates (8%) in the control grou

147 ean time to exacerbation was 240 days in the vitamin D3 group vs 253 days in the placebo group (mean

148 e death was observed in 1 fetus (<1%) in the vitamin D3 group vs 3 fetuses (1%) in the control group

149 adverse events were similar in both groups (vitamin D3 group, n = 11; placebo group, n = 9).

150 uring cold storage and exposure to UV-light, vitamin D3 has been entrapped in microspheres formed by

151 and 3-desoxy-1alpha,25-dihydroxy-2-methylene-vitamin D3 have been synthesized.

152 Moreover, the combination of Grisu(R) and vitamin D3 improves cell viability and decreases ROS pro

153 plementing inhaled corticosteroids with oral vitamin D3 improves outcomes in patients with asthma and

154 ns were correlated, and the dose-response of vitamin D3 in adipose mirrored that in serum.

155 These findings do not support the use of vitamin D3 in adults to prevent depression.

156 Oral vitamin D3 in an initial dose of 200000 IU, followed a m

157 to be 2.4 times more efficient in producing vitamin D3 in human skin than the sun in less than 1/60(

158 tuned to different wavelengths for producing vitamin D3 in human skin.

159 vitamin D3 and 25-hydroxyvitamin D3 in eggs, vitamin D3 in margarine, and vitamin D3 and vitamin D2 i

160 recommended in the recipe, the retention of vitamin D3 in rye bread at 69% was lower than the retent

161 young adults in Cape Town, supplemented with vitamin D3 in winter, to determine whether vitamin D sta

162 mediator production in vitro, as well as the vitamin D3-induced curtailment of PCA responses in WBB6F

163 Vitamin D3 initially given at the time of pulmonary exac

164 By inducing SDF1, vitamin D3 is a novel approach to promote vascular repai

165 This study was planned to assess whether vitamin D3 is a protective factor against acid injury an

166 Vitamin D3 is generated secondary to exposure to ultravi

167 Cholecalciferol or vitamin D3 is known to isomerise under various condition

168 at calcitriol, the hormonally active form of vitamin D3, is an excellent candidate for transmission o

169 ls-Alder reaction confirmed the formation of vitamin D3 isomerisation products.

170 ombined, both the vitamin D3 biscuit and the vitamin D3 juice groups showed a significantly greater a

171 ein (K(A) = 23.5 +/- 1.9 x 10(4) M(-1)) than vitamin D3 (K(A) = 5.8 +/- 1.1 x 10(4) M(-1)).

172 participants with significantly higher serum vitamin D3 levels after treatment (P = 0.007) demonstrat

173 In contrast, participants with lower serum vitamin D3 levels had significant expression of proinfla

174 .5 to 14.0; 62 PFS events) for standard-dose vitamin D3 (log-rank P = .07); multivariable hazard rati

175 ts suggest that Grisu(R) in combination with vitamin D3 may exert a gastroprotective effect to mainta

176 Vitamin D3 may therefore be a preferential form to optim

177 o completed or discontinued chemotherapy and vitamin D3 (median follow-up, 22.9 months), the median P

178 lopment was associated with dysregulation of vitamin D3 metabolism at all stages and plasma 25-hydrox

179 table and protease resistant and include the vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 and

180 failure, where concentrations of the active vitamin D3 metabolite, 1alpha,25-dihydroxyvitamin D3 (1a

181 The vitamin D3 metabolite, 20S,23S-dihydroxyvitamin D3, was

182 n D3 [1,20S(OH)2D3], a natural and bioactive vitamin D3 metabolite, was chemically synthesized for th

183 Bioactive vitamin D3 metabolites 20S,24S-dihydroxyvitamin D3 [20S,

184 We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can r

185 Epidermal-derived vitamin D3 metabolites and PGs provide an essential cue

186 Vitamin D3 metabolites lacking a 1alpha-hydroxyl group (

187 and UVB groups (difference in median of oral vitamin D3 minus that of UVB: 1.5 mg/dL; 95% CI: -5.0, 7

188 e four biweekly doses of 3.5 mg (140,000 IU) vitamin D3 (n = 190) or placebo (n = 200) during intensi

189 5110 participants were randomized to receive vitamin D3 (n = 2558) or placebo (n = 2552).

190 enishment between subjects who received oral vitamin D3 (n = 60) and those who received narrow-band U

191 motherapy every 2 weeks and either high-dose vitamin D3 (n = 69) or standard-dose vitamin D3 (n = 70)

192 gh-dose vitamin D3 (n = 69) or standard-dose vitamin D3 (n = 70) daily until disease progression, int

193 Participants received 1200 IU/d vitamin D3 (n = 77) or placebo tablets (n = 78) for 12 m

194 ities aged 70 years or older, treatment with vitamin D3, omega-3s, or a strength-training exercise pr

195 anation for the anti-inflammatory effects of vitamin D3 on mast cell function by demonstrating that m

196 To determine the effect of high-dose vitamin D3 on response to antimicrobial therapy for PTB

197 Supplementation with 1,25-vitamin D3 or 1,25-vitamin D2 prevented podocyte effacem

198 onary exacerbation, followed by 50,000 IU of vitamin D3 or an identically matched placebo pill taken

199 B1, CYP24A1, and CASR) modify the effects of vitamin D3 or calcium supplementation on colorectal aden

200 s with type 2 diabetes, supplementation with vitamin D3 or omega-3 fatty acids, compared with placebo

201 noma, were randomly assigned to 1000 IU/d of vitamin D3 or placebo and 1200 mg/d of calcium carbonate

202 randomly assigned to receive either 4000 IU vitamin D3 or placebo daily for 24 wk.

203 randomly assigned to receive 3000 IU (75 ug) vitamin D3 or placebo daily for 26 wk.

204 to receive six 2-monthly oral doses of 3 mg vitamin D3 or placebo over 1 year in a 1:1 ratio using c

205 Vitamin D3 or placebo was given orally or via nasogastri

206 eceive 1000 mg/d of calcium plus 400 IU/d of vitamin D3 or placebo.

207 feeding hens at the maximum concentration of vitamin D3 or serum 25-hydroxyvitamin D [25(OH)D3] lawfu

208 ecting vitamin D deficiency with either oral vitamin D3 or UVB does not improve the lipid profile.

209 -controlled, randomised controlled trials of vitamin D3 or vitamin D2 supplementation in people with

210 g vitamin D2, juice supplemented with 15 mug vitamin D3, or biscuit supplemented with 15 mug vitamin

211 C treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed N

212 With vitamin D3, plasma 25(OH)D concentrations peaked at appr

213 mug selenium, 400-mug folic acid, and 20-mug vitamin D3 plus 100-mg calcium) vs placebo and 21 indivi

214 patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo).

215 evels of 25-hydroxyvitamin D3 increased with vitamin D3 plus calcium but not with placebo: Median cha

216 decline in total hip BMD was smaller in the vitamin D3 plus calcium group than in the placebo group:

217 Vitamin D3 plus calcium supplementation mitigates the BM

218 Makarova et al. now show that vitamin D3 produced in the skin by UVR protects against

219 Vitamin D3 produced was independent on the combination o

220 elength of 296nm was found to be optimal for vitamin D3 production.

221 y during winter because of negligible dermal vitamin D3 production.

222 showed different properties with respect to vitamin D3 receptor activation, anti-inflammatory activi

223 of these products were compared in terms of vitamin D3 receptor activation, anti-inflammatory, and a

224 While daily 2000 IU and 800 IU vitamin D3 reduced mean systolic BP over 2 y to a small

225 A high-dose vitamin D3 regimen safely corrected vitamin D deficiency

226 and mouse macrophages due to upregulation of vitamin D3-responsive cathelicidin expression through th

227 Supplementation of mothers with 4400 IU of vitamin D3 resulted in an enhanced broad-spectrum proinf

228 Conversely, the SPR responses obtained for vitamin D3 show that the interactions between this hydro

229 Vitamin D3 significantly promoted RANKL expression in AB

230 ) were administered for 10 days in the SRP + vitamin D3, SRP + vitamin K2, and SRP + vitamins K2 and

231 were randomly assigned to a daily milk-based vitamin D3 supplement of either 10 or 25 ug or placebo (

232 Participants were allocated to 1 year of vitamin D3 supplementation (4,000 IU [100 mug] daily) or

233 50; Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation (CLEAR-PLUS), NCT03576716.

234 High-dosage oral vitamin D3 supplementation attenuated HIV-1 replication,

235 One year of high-dose vitamin D3 supplementation did not improve 6-min walk di

236 Compared with placebo, vitamin D3 supplementation did not significantly improve

237 One year of 100 mug daily vitamin D3 supplementation does not improve 6-min walk d

238 Vitamin D3 supplementation for 24 wk had no significant

239 Our findings suggest that benefits from vitamin D3 supplementation for the prevention of advance

240 We determined whether adjunctive high-dose vitamin D3 supplementation improves outcomes in individu

241 d, double-blind, placebo-controlled trial of vitamin D3 supplementation in adults with COPD in 60 gen

242 aimed to investigate the in vivo sequelae of vitamin D3 supplementation in systemic Candida infection

243 ong individuals with 1 or 2 G alleles (74%), vitamin D3 supplementation increased risk by 41% (RR, 1.

244 Vitamin D3 supplementation may therefore be a useful adj

245 The effect of vitamin D3 supplementation on advanced adenomas, but not

246 olled trial was to investigate the effect of vitamin D3 supplementation on insulin resistance (IR) an

247 ary study there was no significant effect of vitamin D3 supplementation on serum cholesterol profile

248 nvestigated the impact of monthly 100,000 IU vitamin D3 supplementation over several years on cardiov

249 Vitamin D3 supplementation protected against moderate or

250 mong individuals with the AA genotype (26%), vitamin D3 supplementation reduced risk by 64% (RR, 0.36

251 Whether vitamin D3 supplementation reduces severe childhood asth

252 Vitamin D3 supplementation resulted in greater reduction

253 At week 24, vitamin D3 supplementation significantly increased 25(OH

254 -blind, placebo-controlled clinical trial of vitamin D3 supplementation to improve the time to severe

255 The findings do not support the use of vitamin D3 supplementation to prevent severe asthma exac

256 Vitamin D3 supplementation was not associated with the r

257 ficiency in overweight and obese children by vitamin D3 supplementation with 1000 or 2000 IU/d versus

258 persistent asthma and low vitamin D levels, vitamin D3 supplementation, compared with placebo, did n

259 Vitamin D3 supplementation, compared with placebo, likew

260 in tumor volume when mice were subjected to vitamin D3 supplementation.

261 s applied in 2 pilot clinical trials of oral vitamin D3 supplementation.

262 centrations compared with the effect of oral vitamin D3 supplementation.We performed a randomized cli

263 were randomly assigned to receive milk-based vitamin D3 supplements that provided 2 (placebo), 10, or

264 andomly assigned to receive 0, 10, or 20 mug vitamin D3 supplements/d for 20 wk during winter.

265 We measured the extent of vitamin D3 suppression of IgE-mediated mast cell degranu

266 somerisation of both cholecalciferol and pre-vitamin D3 takes place to form trans-vitamin D3 and tach

267 ids; specialized proresolving mediators; and vitamin D3 that have proven immune effects and emerging

268 Vitamin D3, the active form of vitamin D, may counteract

269 Vitamin D3 therefore presents as a low-cost supplementat

270 Vitamin D3 thermally and reversibly transforms to pre-vi

271 of placebo or 4,200, 16,800, or 28,000 IU of vitamin D3 throughout pregnancy.

272 )2D3), the biologically active metabolite of vitamin D3 To further investigate the mechanism of this

273 Terminal activation of vitamin D3 to its hormonal form, 1alpha,25-dihydroxyvita

274 on of high-dose vitamin D3, vs standard-dose vitamin D3, to standard chemotherapy resulted in a diffe

275 sphate-treated VSMCs and aortic rings and in vitamin D3-treated mice.

276 Moreover, vitamin D3 treatment decreased interferon-gamma-positive

277 3 thermally and reversibly transforms to pre-vitamin D3 type isomers.

278 nteractions of beta-casein with curcumin and vitamin D3 under the same physico-chemical conditions we

279 Vitamin D3, used as a model nutraceutical, was successfu

280 a(ep-/-)) or a topical application of active vitamin D3 (VD3) and/or all-trans retinoic acid (RA) on

281 most potent among them - can also metabolize vitamin D3 (VD3) derivatives.

282 We sought to determine the effect of CS on vitamin D3 (VD3) levels, conversion, and regulation of C

283 ntify coeluted vitamin E succinate (VES) and vitamin D3 (VD3).

284 For this study, model drug (vitamin D3, VD3)-loaded PLGA nano- and microparticles (N

285 calciferol (vitamin D2) and cholecalciferol (vitamin D3) (vitamin D) and 25-hydroxivitamin D2 plus D3

286 Vitamin D3 (vitD3) and its active metabolite, calcitriol

287 re is currently widespread interest in using vitamin D3 (VitD3) as an adjunct therapy for TB because

288 (95% CI, -13.4 to -11.2) mL/min/1.73 m2 with vitamin D3 vs -13.1 (95% CI, -14.2 to -11.9) mL/min/1.73

289 study groups: 20.1 days (IQR, 12.9-39.1) for vitamin D3 vs 19.0 days (IQR, 11.6-33.8) for placebo.

290 s with metastatic CRC, addition of high-dose vitamin D3, vs standard-dose vitamin D3, to standard che

291 y 1, mean change (baseline to 3 mo) in serum vitamin D3 was -0.1 ng/mL in the placebo group and 6.8 n

292 y 2, mean change (baseline to 3 mo) in serum vitamin D3 was 10.4 ng/mL in the 2000 IU/d group and 22.

293 , 22.9 months), the median PFS for high-dose vitamin D3 was 13.0 months (95% CI, 10.1 to 14.7; 49 PFS

294 dian 25(OH)D level at baseline for high-dose vitamin D3 was 16.1 ng/mL vs 18.7 ng/mL for standard-dos

295 The combined effect of Grisu(R) and vitamin D3 was found more effective in counteracting the

296 s relevant to food-fortification strategies, vitamin D3 was more effective than vitamin D2 in increas

297 Prespecified subgroup analysis showed that vitamin D3 was protective against moderate or severe exa

298 h 4400 IU/d (n = 26) or 400 IU/d (n = 25) of vitamin D3 were analyzed for immune cell composition by

299 chemotherapy plus high-dose vs standard-dose vitamin D3 were neutropenia (n = 24 [35%] vs n = 21 [31%

300 ions, and oxidation, on the isomerisation of vitamin D3 were studied using HPLC-DAD and UHPLC-MS/MS.